

Hemophilia

Mohammad Faranoush, MD

Associate Professor, Pediatric Hematologist Oncologist, IBTO Member

Inherited bleeding disorder is named generally hemophilia, in which the blood does not clot appropriately. Blood contains wide variety of different hemostatic proteins, which called clotting factors. These factors involved in hemostatic cascade. Patients with hemophilia have either deficient or a low level of these clotting factors. In some diseases the lower levels of plasma factors causes, severe forms the hemophilia with serious symptoms and signs of bleeding. In contrast, some forms of hemophilia such as factor XI deficiency don't have any relationship between the symptoms and factor level. Hemophilia patients must do following the 5"Tips for Healthy Living as below:

1. Routine standard comprehensive checkup at a hemophilia treatment center
2. Vaccination against Hepatitis B
3. Educate, how to treat bleeding episode as early and adequately.
4. Home treatment ,and rehabilitation after bleeding, healthy weight to protect joints
5. Maintain sport and Social activities

Hemophilia is a chronic and complex disease. Comprehensive medical care with good quality and experts, Caring and conscientious physician, nurses and other medical team can prevent complications of disease. Inhibitors can develop in 10-15% of people with hemophilia. These patients have increased bleeding episode, reduced quality of life, and increased cost of treatment. The available products is FEIBA and Novoseven to control bleeding episodes. Recently Iranian colleagues produced biosimilar RFXIIa that used in double blind, multi center clinical trial study on factor VII deficient patients. Also IBTO signed a contract with some companies for plasma fractionation. According to WFH report, only 25 per cent of people with bleeding disorders have access to treatment. The multidisciplinary caring program causes better patient healthcare, and lifestyle, also equity in treatment. We hope with increasing availability clotting factor concentrates products and RFXIIa, Hemophilia patients experienced ideal treatment.